MannKind | MNKD - Selling And Administration Expenses


MannKind reported $58.3M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Adma Biologics USD 26.74M 6.55M Mar/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Halozyme Therapeutics USD 57M 10.71M Jun/2026
Insmed USD 247.47M 208K Jun/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
MacroGenics USD 9.71M 1.77M Mar/2026
MannKind USD 58.3M 4.22M Jun/2026
Merck USD 2.89B 219M Jun/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Novavax USD 25.53M 1.34M Dec/2025
Novo Nordisk DKK 2.54B 10.68B Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
Xencor USD 77.54M 4.59M Jun/2026